allergan plc (AGN:New York Consolidated)
Transactions by ALLERGAN PLC (AGN) in the last 6 months
Allergan plc (NYSE:AGN) entered into an agreement to acquire AqueSys, Inc. from Accuitive Medical Ventures, LLC, SV Life Sciences Advisers, LLC, Longitude Capital Management Co., LLC, The Innovation Factory, LLC and others for $300 million in cash on September 3, 2015. Under the terms of the agreement, Allergan will acquire AqueSys for a $300 million upfront payment and regulatory approval and commercialization milestone payments related to AqueSys' lead development ...
Carlyle Venture Partners II, L.P.
Longitude Capital Management Co., LLC
Rho Capital Partners, Inc.
SV Life Sciences Advisers, LLC
The Carlyle Group LP
The Innovation Factory, LLC
McDermott Will & Emery LLP
Teva Pharmaceutical Industries Limited (NYSE:TEVA) signed a definitive agreement to acquire Allergan Generics from Allergan plc (NYSE:AGN) for $40.5 billion in cash and stock on July 26, 2015. On closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing a 10% ownership stake in Teva. Allergan Generics is being acquired as cash free and debt free basis. Teva will pay Allergan $33.75 billion in cash which will ...
Allergan plc (NYSE:AGN) entered into a definitive agreement to acquire Naurex, Inc. from a group of shareholders for $560 million in cash on July 26, 2015. The group of shareholders include Adams Street Partners, LLC, Latterell Venture Partners, Druid BioVentures, Genesys Capital Partners Inc., H. Lundbeck A.S, Investment Arm, Takeda Ventures, Inc., Baxter Ventures, Savitr Capital, LLC, Northwestern University, Endowment Arm, Shire Strategic Investment Group, PathoCapital, ...
Cowen Group, Inc.
Cowen Investments I, LLC
Ecor1 Capital, LLC
Genesys Capital Partners Inc.
Goudy Park Capital
H. Lundbeck A.S, Investment Arm
Latterell Venture Partners
Northwestern University, Endowment Arm
Portola Capital Partners
Savitr Capital, LLC
Shire Strategic Investment Group
Takeda Ventures, Inc.
Allergan plc (NYSE:AGN) entered into an agreement to acquire exclusive worldwide rights to CGRP Migraine Development program from Merck & Co. Inc. (NYSE:MRK) for $250 million on July 7, 2015. Under the terms of the agreement, Allergan will acquire the rights for an upfront payment of $250 million, $125 million of which is payable upon HSR clearance and $125 million of which is payable in April of 2016. Additionally, Merck will be entitled to receive potential development ...
Allergan plc (NYSE:AGN) entered into an agreement to acquire Oculeve, Inc. from Versant Ventures, Inc., New Enterprise Associates, Kleiner Perkins Caufield & Byers and others for approximately $130 million in cash on July 6, 2015. The consideration includes additional commercialization milestone payments related to Oculeve's lead development program OD-01. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program. The ...
New Enterprise Associates
Versant Ventures, Inc.
Wilson, Sonsini, Goodrich & Rosati
Allergan plc (NYSE:AGN) entered into an agreement and plan of merger to acquire Kythera Biopharmaceuticals, Inc. (NasdaqGS:KYTH) from a group of investors for $1.9 billion in cash and stock on June 17, 2015. The sellers are Versant Ventures, Inc., Prospect Venture Partners, Altitude Life Science Ventures, UCLA Ventures, Fidelity Management & Research Company, Partner Fund Management, L.P., Investor Growth Capital, Palo Alto Investors, LLC and other shareholders. Under ...
Fidelity Management & Research Company
Investor Growth Capital
Palo Alto Investors, LLC
Partner Fund Management, L.P.
Prospect Venture Partners
Versant Ventures, Inc.
|Amgen Inc||$141.22 USD||-2.58|
|Bristol-Myers Squibb Co||$59.88 USD||-2.09|
|Eli Lilly & Co||$84.17 USD||-2.40|
|Medtronic PLC||$69.92 USD||-0.95|
|Novo Nordisk A/S||kr367.00 DKK||+0.70|
|View Industry Companies|